This monthly update explains why stocks in the Activist Investor portfolio tend not to follow the wild gyrations of market volatility, while also providing a look at most of the recommendations in the portfolio.
The Activist Investor goal is to buy shares before they soar: investing in activist campaign stocks that have been sold off to their lowest levels… then benefit as these companies begin to turn around and prosper.
This promising producer of next-generation digital and power devices caught the eye of an activist investor who is pushing hard to get the company to turn the billions it invested in new plants into exponential revenue growth.
With the share price down and with a handful of catalysts likely to drive the price higher, we provide an update on V.F. Corporation – and look at three other stocks in the portfolio as well: OneSpan, Orthofix Medical, and Mercury Systems.
This cybersecurity and digital-documents company has been the target of an activist since 2018 – now steady progress is about to show up in the financials and drive shares higher.
The Activist Investor portfolio continues to ride the waves of volatility. This update reports on those up and down movements and on some exciting things that have happened across all our stocks.
While this company may not be familiar to many people, its iconic brands certainly are. But because of corporate missteps, the owner of these gear and apparel makers has hit hard times — which we now see as an opportunity
Action to Take: Buy Shares of Mercury Systems (MRCY) On February 6, after the market closed, Mercury Systems (Nasdaq: MRCY) reported earnings for its second quarter 2024 fiscal year – for the period ending December 2023. As is often the case with companies in a turnaround mode, the results were not good. In fact, company
On February 5, drug manufacturer Catalent (NYSE: CTLT) announced it would sell itself to Novo Nordisk (NYSE: NVO) for $63.50 per share in cash – about $11.5 billion in total. This share price is a 17% premium to the prior closing price of $54.51 on Friday, February 2, and an increase of 40% since we
In this issue, we focus on a medical-device company that specializes in both orthopedic and spinal products used by doctors and surgeons across the globe. A mismanaged merger and other changes in strategy have sent the stock to record lows. Now, with an activist investor involved, we see good things happening for this company.